![EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field' EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field'](https://www.biopharma-reporter.com/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/pharmaceutical-science/biopharma-reporter.com/article/2021/11/30/ema-to-review-atara-s-maa-submission-for-allogeneic-t-cell-therapy-a-watershed-moment-for-the-field/13052871-1-eng-GB/EMA-to-review-Atara-s-MAA-submission-for-allogeneic-T-cell-therapy-A-watershed-moment-for-the-field.jpg)
EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field'
![Transfert d'Atara à Pierre Fabre de l'AMM accordée par la Commission européenne à EBVALLO | MyPharma Editions Transfert d'Atara à Pierre Fabre de l'AMM accordée par la Commission européenne à EBVALLO | MyPharma Editions](https://www.mypharma-editions.com/wordpress/wp-content/uploads/2023/02/2023-02-08_132548.jpg)
Transfert d'Atara à Pierre Fabre de l'AMM accordée par la Commission européenne à EBVALLO | MyPharma Editions
![Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News](https://static.stocktitan.net/company-logo/ATRA-lg.png)
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | ATRA Stock News
![Em negócio de até US$ 640 milhões, Pierre Fabre dobra sua parceria de células T com Atara - Guia da Farmácia Em negócio de até US$ 640 milhões, Pierre Fabre dobra sua parceria de células T com Atara - Guia da Farmácia](https://guiadafarmacia.com.br/wp-content/uploads/2023/11/Pierre-Fabre-nova-sede-1.jpg)
Em negócio de até US$ 640 milhões, Pierre Fabre dobra sua parceria de células T com Atara - Guia da Farmácia
![Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617) Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617)](https://www.moneycontroller.fr/upload/aziende/atara-biotherapeutics-inc_20210427131418.png)
Atara Biotherapeutics Inc.: Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress - Form 8-K - MoneyController (ID 1539617)
![Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire](https://mms.businesswire.com/media/20231031702630/en/792504/23/Atara-Bio1_logo_300x185-1.jpg)
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results | Business Wire
![Pierre Fabre va commercialiser et distribuer la première immunothérapie allogénique à lymphocytes T en Europe suite au transfert de l'autorisation de mise sur le marché accordée par la Commission européenne pour EBVALLO® ( Pierre Fabre va commercialiser et distribuer la première immunothérapie allogénique à lymphocytes T en Europe suite au transfert de l'autorisation de mise sur le marché accordée par la Commission européenne pour EBVALLO® (](https://mma.prnewswire.com/media/1970795/Pierre_Fabre_Atara_Logo.jpg?p=facebook)
Pierre Fabre va commercialiser et distribuer la première immunothérapie allogénique à lymphocytes T en Europe suite au transfert de l'autorisation de mise sur le marché accordée par la Commission européenne pour EBVALLO® (
![Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | Business Wire Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | Business Wire](https://mms.businesswire.com/media/20231220458866/en/1976254/23/Atara-Bio1_R_whtbox_3000px20190319.jpg)
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories | Business Wire
![Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online](https://medicalupdateonline.com/wp-content/uploads/2023/12/AdobeStock_366674524_Editorial_Use_Only.jpg)
Atara Biotherapeutics announces closing of expanded global Tab Cel partnership with Pierre Fabre Labs - Medical Update Online
![Pierre Fabre : le CHMP recommande l'approbation d'Ebvallo d'Atara Biotherapeutics | MyPharma Editions Pierre Fabre : le CHMP recommande l'approbation d'Ebvallo d'Atara Biotherapeutics | MyPharma Editions](https://www.mypharma-editions.com/wordpress/wp-content/uploads/2022/10/2022-10-14_133833.jpg)
Pierre Fabre : le CHMP recommande l'approbation d'Ebvallo d'Atara Biotherapeutics | MyPharma Editions
![Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally](https://pharmashots.com/public/images/20221220185253_original_35.webp)
Atara Biotherapeutics Expands its Collaboration Agreement with Laboratoires Pierre Fabre to Develop and Commercialize Ebvallo Globally
![Les Laboratoires Pierre Fabre accélèrent leur développement dans le domaine de l'onco-hématologie grâce à l'acquisition aux Etats-Unis d'une licence pour une immunothérapie à lymphocytes T Les Laboratoires Pierre Fabre accélèrent leur développement dans le domaine de l'onco-hématologie grâce à l'acquisition aux Etats-Unis d'une licence pour une immunothérapie à lymphocytes T](https://mma.prnewswire.com/media/1328780/Pierre_Fabre_Logo.jpg?p=facebook)